CN105073740A - 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 - Google Patents

一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 Download PDF

Info

Publication number
CN105073740A
CN105073740A CN201480009595.5A CN201480009595A CN105073740A CN 105073740 A CN105073740 A CN 105073740A CN 201480009595 A CN201480009595 A CN 201480009595A CN 105073740 A CN105073740 A CN 105073740A
Authority
CN
China
Prior art keywords
bms
bis
scholars
preparation
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480009595.5A
Other languages
English (en)
Other versions
CN105073740B (zh
Inventor
胡晨阳
盛晓霞
盛晓红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Ling Ye Pharmaceutical Technology Co., Ltd
Original Assignee
Hangzhou Pushai Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Pushai Pharmaceutical Technology Co ltd filed Critical Hangzhou Pushai Pharmaceutical Technology Co ltd
Priority to CN201610661880.6A priority Critical patent/CN106279121B/zh
Priority to CN201610664633.1A priority patent/CN106279122A/zh
Publication of CN105073740A publication Critical patent/CN105073740A/zh
Application granted granted Critical
Publication of CN105073740B publication Critical patent/CN105073740B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

提供化合物((IS)-1-(((2S)-2-(5-(4ˊ-(2-((2S)-1-((2S)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1H-咪唑-5-基)-4-联苯基)-1H-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯的盐及其晶型和无定形物，还提供了所述盐及其晶型和无定形物的制备方法、药物组合物和制药用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201480009595.5A 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 Active CN105073740B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610661880.6A CN106279121B (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN201610664633.1A CN106279122A (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/071020 WO2015109445A1 (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610661880.6A Division CN106279121B (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN201610664633.1A Division CN106279122A (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Publications (2)

Publication Number Publication Date
CN105073740A true CN105073740A (zh) 2015-11-18
CN105073740B CN105073740B (zh) 2017-06-27

Family

ID=53680561

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610664633.1A Pending CN106279122A (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN201480009595.5A Active CN105073740B (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN201610661880.6A Active CN106279121B (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610664633.1A Pending CN106279122A (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610661880.6A Active CN106279121B (zh) 2014-01-21 2014-01-21 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途

Country Status (2)

Country Link
CN (3) CN106279122A (zh)
WO (1) WO2015109445A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109496214A (zh) * 2016-07-22 2019-03-19 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3237405A1 (en) 2014-12-26 2017-11-01 Cipla Limited Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
CZ2015366A3 (cs) * 2015-05-29 2016-12-07 Zentiva, K.S. Pevné formy Daclatasviru
WO2017021904A1 (en) * 2015-08-03 2017-02-09 Laurus Labs Private Limited Daclatasvir free base and process for the preparation thereof
CN105153128A (zh) * 2015-10-15 2015-12-16 上海众强药业有限公司 一种合成达卡他韦中间体的新方法
CN105566303A (zh) * 2016-01-25 2016-05-11 上海众强药业有限公司 达卡他韦新晶型及其制备方法
CN106188016A (zh) * 2016-07-04 2016-12-07 福建广生堂药业股份有限公司 盐酸达卡他韦的二水合物及其制备方法
CN108675998B (zh) * 2018-06-28 2019-08-13 北京凯因格领生物技术有限公司 一种结晶性氨基甲酸甲酯类化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
JP2014527061A (ja) * 2011-08-24 2014-10-09 グラクソスミスクライン エルエルシー Ｃ型肝炎の組合せ治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109496214A (zh) * 2016-07-22 2019-03-19 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Also Published As

Publication number Publication date
CN106279122A (zh) 2017-01-04
CN105073740B (zh) 2017-06-27
CN106279121A (zh) 2017-01-04
CN106279121B (zh) 2019-05-24
WO2015109445A1 (zh) 2015-07-30

Similar Documents

Publication Publication Date Title
CN105073740A (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN105693624B (zh) 马西替坦晶体及其制备方法、其药物组合物和用途
EP3174889B1 (en) Sofosbuvir in crystalline form and process for its preparation
CN104284897B (zh) 替卡格雷晶型及其制备方法和用途
CN105121409B (zh) 德罗格韦钠盐的晶型及其制备方法
CN103298805A (zh) 喹唑啉化合物及其使用方法
CN105121434A (zh) 坎格列净一水合物及其晶型、它们的制备方法和用途
WO2019019959A1 (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
CN110128356A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
CN105188699A (zh) 恩杂鲁胺的固态形式及其制备方法和用途
CN110312705B (zh) Gft-505的晶型及其制备方法和用途
CN110156700A (zh) 吉非替尼与水杨酸共晶体
CN104540822A (zh) 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2014036865A1 (zh) 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105193749A (zh) 一种治疗泌尿外科类疾病的药物他达拉非组合物片剂
CN103059013B (zh) 达沙替尼一水合物的晶型及其制备方法
CN104936947B (zh) 氯卡色林盐及其晶体、其制备方法和用途
CN106928228A (zh) 奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN112194624A (zh) 一种异喹啉类化合物的晶型及其制备方法
CN101316593B (zh) 喹啉酮类的制剂
CN105566294A (zh) 一种右旋艾普拉唑钠化合物及其药物组合物
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105232483A (zh) 一种治疗泌尿外科疾病的药物他达拉非组合物片剂
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190821

Address after: 310018 Room 2B05, Building 452, No. 6 Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province

Patentee after: Hangzhou Ling Ye Pharmaceutical Technology Co., Ltd

Address before: 310018 room 2B12, building 452, No. 6, Hangzhou Economic & Technological Development Zone, Hangzhou, Zhejiang, China

Patentee before: HANGZHOU PUSHA PHARMACEUTICAL TECHNOLOGY CO., LTD.

TR01 Transfer of patent right